

## Daftar Pustaka

- Abbas, A. K., Lichtman, A. H., & Pillai, S. (2018). Immunity to Tumors. In *Cellular and molecular immunology E-book* (9e ed.). Elsevier Health Sciences.
- Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018). Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy. *Frontiers in Immunology*, 9, 527. <http://files/130/contribution-to-tumor-angiogenesis-from-innate-immune-cells-with-2018.pdf>
- Bhatla, N., Berek, J. S., Fredes, M. C., Denny, L. A., Grenman, S., Karunaratne, K., Kehoe, S. T., Konishi, I., Olawaiye, A. B., & Prat, J. (2019). Revised FIGO staging for carcinoma of the cervix uteri. *International Journal of Gynecology & Obstetrics*, 145(1), 129–135. <http://files/215/Bhatla et al. - 2019 - Revised FIGO staging for carcinoma of the cervix u.pdf>
- Blomberg, O. S., Spagnuolo, L., & de Visser, K. E. (2018). Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. *Disease Models & Mechanisms*, 11(10), dmm036236.
- Bosch, F. X., Manos, M. M., Muñoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., & Shan, K. V. (1995). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. *JNCI: Journal of the National Cancer Institute*, 87(11), 796–802.
- Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., & Croce, C. M. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proceedings of the National Academy of Sciences of the United States of America*, 101(9), 2999–3004. <https://doi.org/10.1073/pnas.0307323101>
- Carcangiu, M. L., Kurman, R. J., Carcangiu, M. L., & Herrington, C. S. (2014). Tumors of the uterine cervix. In *WHO classification of tumours of female reproductive organs* (4th ed., pp. 172–181). International Agency for Research on Cancer.
- Chen, J., Jiang, C. C., Jin, L., & Zhang, X. D. (2016). Regulation of PD-L1: a novel role of pro-survival signalling in cancer. *Annals of Oncology*, 27(3), 409–416. <http://files/225/Chen et al. - 2016 - Regulation of PD-L1 a novel role of pro-survival .pdf>
- Chen, Z., Schiffman, M., Herrero, R., DeSalle, R., Anastos, K., Segondy, M., Sahasrabudde, V. V., Gravitt, P. E., Hsing, A. W., & Chan, P. K. S. (2018). Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61). *Virology*, 516, 86–101.
- Damjanov, I., & Fan, F. (2007). Tumor of the Female Genital Organs. In *Cancer grading manual* (2nd ed., pp. 112–117). Springer.
- Dieci, M. V., Radosevic-Robin, N., Fineberg, S., van den Eynden, G., Ternes, N., Penault-Llorca, F., Pruneri, G., D'Alfonso, T. M., Demaria, S., Castaneda, C., Sanchez, J., Badve, S., Michiels, S., Bossuyt, V., Rojo, F., Singh, B., Nielsen, T., Viale, G., Kim, S. R., ... Salgado, R. (2018). Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immunology Biomarker Working Group on Bre. *Seminars in Cancer Biology*, 52(September 2017), 16–25. <https://doi.org/10.1016/j.semcancer.2017.10.003>
- Dong, P., Xiong, Y., Yu, J., Chen, L., Tao, T., Yi, S., Hanley, S. J. B., Yue, J., Watari, H., & Sakuragi, N. (2018). Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4–miR-18a pathway in cervical cancer. *Oncogene*,

37(39), 5257–5268. <https://doi.org/10.1038/s41388-018-0347-4>

- Dong, Y., Sun, Q., & Zhang, X. (2017). PD-1 and its ligands are important immune checkpoints in cancer. *Oncotarget*, 8(2), 2171. <http://files/221/Dong et al. - 2017 - PD-1 and its ligands are important immune checkpoi.pdf>
- Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. *Nature Immunology*, 3(11), 991–998. <http://files/234/Cancer immunoediting.pdf>
- Gómez-Gómez, Y., Organista-Nava, J., & Gariglio, P. (2013). Deregulation of the miRNAs expression in cervical cancer: Human papillomavirus implications. *BioMed Research International*, 2013(Cc). <https://doi.org/10.1155/2013/407052>
- Gu, X., Dong, M., Liu, Z., Mi, Y., Yang, J., Zhang, Z., Liu, K., Jiang, L., Zhang, Y., Dong, S., & Shi, Y. (2019). Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer. *Cancer Cell International*, 19(1), 146. <https://doi.org/10.1186/s12935-019-0861-7>
- Guo, L., Lin, Y., & Fai Kwok, H. (2017). The function and regulation of PD-L1 in immunotherapy. *ADMET and DMPK*, 5(3), 159–172.
- Habbous, S., Pang, V., Xu, W., Amir, E., & Liu, G. (2014). Human papillomavirus and host genetic polymorphisms in carcinogenesis: A systematic review and meta-analysis. *Journal of Clinical Virology*, 61(2), 220–229.
- He, J., Hu, Y., Hu, M., & Li, B. (2015). Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. *Scientific Reports*, 5(1), 1–9. <http://files/229/Development of PD-1 PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.pdf>
- He, Y., Lin, J., Ding, Y., Liu, G., Luo, Y., Huang, M., Xu, C., Kim, T.-K., Etheridge, A., & Lin, M. (2016). A systematic study on dysregulated micro RNA s in cervical cancer development. *International Journal of Cancer*, 138(6), 1312–1327. <http://files/237/A Systematic Study on Dysregulated microRNAs in Cervical Cancer Development.pdf>
- He, Y., Lin, J., Ding, Y., Liu, G., Luo, Y., Huang, M., Xu, C., Kim, T. K., Etheridge, A., Lin, M., Kong, D., & Wang, K. (2016). A systematic study on dysregulated microRNAs in cervical cancer development. *International Journal of Cancer*, 138(6), 1312–1327. <https://doi.org/10.1002/ijc.29618>
- Hoppe-Seyler, K., Bossler, F., Braun, J. A., Herrmann, A. L., & Hoppe-Seyler, F. (2018). The HPV E6/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets. *Trends in Microbiology*, 26(2), 158–168.
- Jhingran, A., Russell, A. H., Seiden, M. V., Duska, L. R., Goodman, A., Lee, S. L., Digumarthy, S. R., & Fuller, A. F. (2020). Cancers of the cervix, vulva, and vagina. In *Abeloff's Clinical Oncology* (pp. 1468-1507. e8). Elsevier.
- Katki, H. A., Schiffman, M., Castle, P. E., Fetterman, B., Poitras, N. E., Lorey, T., Cheung, L. C., Raine-Bennett, T., Gage, J. C., & Kinney, W. K. (2013). Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results. *Journal of Lower Genital Tract Disease*, 17(5 Suppl 1), S50-5. <https://doi.org/10.1097/LGT.0b013e3182854282>
- Koh, W.-J., Abu-Rustum, N. R., Bean, S., Bradley, K., Campos, S. M., Cho, K. R., Chon, H. S., Chu, C., Clark, R., & Cohn, D. (2019). Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network*, 17(1), 64–84. <http://files/219/Koh et al. - 2019 - Cervical cancer, version>

3.2019, NCCN clinical pra.pdf

- Kumar, V., Abbas, A. K., & Aster, J. C. (2017a). Female Genital System and Breast. In *Robbins basic pathology e-book* (10th ed., pp. 717–721). Elsevier Health Sciences.
- Kumar, V., Abbas, A. K., & Aster, J. C. (2017b). Neoplasia. In *Robbins basic pathology e-book* (10th ed., pp. 189–242). Elsevier Health Sciences.
- Kumar, V., Abbas, A. K., Fausto, N., & Aster, J. C. (2014). The Cell as Unit of Health and Disease. In *Robbins and Cotran pathologic basis of disease, professional edition e-book* (10ed ed., pp. 1–6). Elsevier health sciences.
- Lee, L., & Garland, S. M. (2017). Human papillomavirus vaccination: the population impact. *F1000Research*, 6.
- Lin, W., Chen, M., Hong, L., Zhao, H., & Chen, Q. (2018). Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. *Frontiers in Oncology*, 8. <https://doi.org/10.3389/fonc.2018.00532>
- Liu, C., Lu, J., Tian, H., Du, W., Zhao, L., Feng, J., Yuan, D., & Li, Z. (2017). Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity. *Molecular Medicine Reports*, 15(3), 1063–1070. <https://doi.org/10.3892/mmr.2017.6102>
- Liu, Y., Lu, Z., Xu, R., & Ke, Y. (2016). Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology. *Oncotarget*, 7(5), 5852–5864. <https://doi.org/10.18632/oncotarget.6809>
- Maskey, N., Thapa, N., Maharjan, M., Shrestha, G., Maharjan, N., Cai, H., & Liu, S. (2019). Infiltrating CD4 and CD8 lymphocytes in hpv infected uterine cervical milieu. *Cancer Management and Research*, 11, 7647–7655. <https://doi.org/10.2147/CMAR.S217264>
- Meng, Y., Liang, H., Hu, J., Liu, S., Hao, X., Wong, M. S. K., Li, X., & Hu, L. (2018). PD-L1 Expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer. *Journal of Cancer*, 9(16), 2938. <http://files/184/Meng et al. - 2018 - PD-L1 Expression correlates with tumor infiltratin.pdf>
- Mezache, L., Paniccia, B., Nyinawabera, A., & Nuovo, G. J. (2015). Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. *Modern Pathology*, 28(12), 1594. <http://files/150/Mezache et al. - 2015 - Enhanced expression of PD L1 in cervical intraepit.pdf>
- Munoz, N., Kjaer, S. K., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., & Tay, E. H. (2010). Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. *Journal of the National Cancer Institute*, 102(5), 325–339.
- Nicolás, I., Marimon, L., Barnadas, E., Saco, A., Rodríguez-Carunchio, L., Fusté, P., Martí, C., Rodríguez-Trujillo, A., Torne, A., Del Pino, M., & Ordi, J. (2019). HPV-negative tumors of the uterine cervix. *Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc*, 32(8), 1189–1196. <https://doi.org/10.1038/s41379-019-0249-1>
- Patel, C., Brotherton, J. M. L., Pillsbury, A., Jayasinghe, S., Donovan, B., Macartney, K., & Marshall, H. (2018). The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? *Eurosurveillance*, 23(41).
- Rice, A. E., Latchman, Y. E., Balint, J. P., Lee, J. H., Gabitzsch, E. S., & Jones, F. R. (2015). An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor

- regression and reduction in PD-L1 expression. *Cancer Gene Therapy*, 22(9), 454. <http://files/158/Rice et al. - 2015 - An HPV-E6E7 immunotherapy plus PD-1 checkpoint in.pdf>
- Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., Perez, E. A., Thompson, E. A., Symmans, W. F., Richardson, A. L., Brock, J., Criscitiello, C., Bailey, H., Ignatiadis, M., Floris, G., ... Loi, S. (2015). The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILS Working Group 2014. *Annals of Oncology*, 26(2), 259–271. <https://doi.org/10.1093/annonc/mdu450>
- Salgado, Roberto, Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., & Pénault-Llorca, F. (2015). The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Annals of Oncology*, 26(2), 259–271. [http://files/200/Salgado et al. - 2015 - The evaluation of tumor-infiltrating lymphocytes \(.pdf](http://files/200/Salgado et al. - 2015 - The evaluation of tumor-infiltrating lymphocytes (.pdf)
- Santin, A. D., Bellone, S., Palmieri, M., Bossini, B., Roman, J. J., Cannon, M. J., Bignotti, E., Canè, S., & Pecorelli, S. (2003). Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. *Gynecologic Oncology*, 89(2), 271–280.
- Santini, F. C., & Hellmann, M. D. (2018). PD-1/PD-L1 Axis in Lung Cancer. *Cancer Journal (Sudbury, Mass.)*, 24(1), 15–19. <http://files/156/Santini and Hellmann - 2018 - PD-1PD-L1 Axis in Lung Cancer..pdf>
- Schiffman, M., Doorbar, J., Wentzensen, N., de Sanjosé, S., Fakhry, C., Monk, B. J., Stanley, M. A., & Franceschi, S. (2016). Carcinogenic human papillomavirus infection. *Nature Reviews. Disease Primers*, 2, 16086. <https://doi.org/10.1038/nrdp.2016.86>
- Shah, W., Yan, X., Jing, L., Zhou, Y., Chen, H., & Wang, Y. (2011). A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. *Cellular and Molecular Immunology*, 8(1), 59–66. <https://doi.org/10.1038/cmi.2010.56>
- Shah, W., Yan, X., Jing, L., Zhou, Y., Chen, H., Wang, Y., He, Y., Lin, J., Ding, Y., Liu, G. G., Luo, Y., Huang, M., Xu, C., Kim, T.-K., Etheridge, A., Lin, M., Rice, A. E., Latchman, Y. E., Balint, J. P., ... Herrington, C. S. (2018). Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia. *Cancer Management and Research*, 8(2), 454. <https://doi.org/10.18632/oncotarget.11722>
- Stevanović, S., Draper, L. M., Langan, M. M., Campbell, T. E., Kwong, M. L., Wunderlich, J. R., Dudley, M. E., Yang, J. C., Sherry, R. M., Kammula, U. S., Restifo, N. P., Rosenberg, S. A., & Hinrichs, C. S. (2015). Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. *Journal of Clinical Oncology*, 33(14), 1543–1550. <https://doi.org/10.1200/JCO.2014.58.9093>
- Sun, C., Mezzadra, R., & Schumacher, T. N. (2018). Regulation and function of the PD-L1 checkpoint. *Immunity*, 48(3), 434–452. <http://files/223/Sun et al. - 2018 - Regulation and function of the PD-L1 checkpoint.pdf>
- Syrjänen, S. M., & Syrjänen, K. J. (1999). New concepts on the role of human papillomavirus in cell cycle regulation. *Annals of Medicine*, 31(3), 175–187.

- Tainio, K., Athanasiou, A., Tikkinen, K. A. O., Aaltonen, R., Cárdenas, J., Hernández, Glazer-Livson, S., Jakobsson, M., Joronen, K., Kiviharju, M., Louvanto, K., Oksjoki, S., Tähtinen, R., Virtanen, S., Nieminen, P., Kyrgiou, M., & Kalliala, I. (2018). Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. *BMJ (Clinical Research Ed.)*, *360*, k499–k499. <https://doi.org/10.1136/bmj.k499>
- Wang, Q., Lin, W., Tang, X., Li, S., Guo, L., Lin, Y., & Kwok, H. F. (2017). The roles of microRNAs in regulating the expression of PD-1/PD-L1 immune checkpoint. *International Journal of Molecular Sciences*, *18*(12), 2540. <http://files/188/Wang et al. - 2017 - The roles of microRNAs in regulating the expressio.pdf>
- Wang, X., Wang, H.-K., Li, Y., Hafner, M., Banerjee, N. S., Tang, S., Briskin, D., Meyers, C., Chow, L. T., & Xie, X. (2014). microRNAs are biomarkers of oncogenic human papillomavirus infections. *Proceedings of the National Academy of Sciences*, *111*(11), 4262–4267. <http://files/186/Wang et al. - 2014 - microRNAs are biomarkers of oncogenic human papill.pdf>
- Yaghoubi, N., Soltani, A., Ghazvini, K., Hassanian, S. M., & Hashemy, S. I. (2019). PD-1/PD-L1 blockade as a novel treatment for colorectal cancer. *Biomedicine and Pharmacotherapy*, *110*(September 2018), 312–318. <https://doi.org/10.1016/j.biopha.2018.11.105>
- Yang-Chun, F., Zhen-Zhen, C., Yan-Chun, H., & Xiu-Min, M. (2017). Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients. *Medicine*, *96*(25). <http://files/357/Association between PD-L1 and HPV status and.pdf>
- Yang, W., Song, Y., Lu, Y.-L., Sun, J.-Z., & Wang, H.-W. (2013). Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. *Immunology*, *139*(4), 513–522. [http://files/213/Yang et al. - 2013 - Increased expression of programmed death \(PD\)-1 an.pdf](http://files/213/Yang et al. - 2013 - Increased expression of programmed death (PD)-1 an.pdf)

## LAMPIRAN

Data

### Diagnosis

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	LSIL	13	28.3	28.9	28.9
	HSIL	15	32.6	33.3	62.2
	SCC	17	37.0	37.8	100.0
	Total	45	97.8	100.0	
Missing	System	1	2.2		
Total		46	100.0		

### TILS\_Percentage


		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	<5%	11	23.9	24.4	24.4
	5-10%	14	30.4	31.1	55.6
	>10%	20	43.5	44.4	100.0
	Total	45	97.8	100.0	
Missing	System	1	2.2		
Total		46	100.0		

**PDL1**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Negatif	8	17.4	17.8	17.8
	Low	25	54.3	55.6	73.3
	Moderate	8	17.4	17.8	91.1
	High	4	8.7	8.9	100.0
	Total	45	97.8	100.0	
Missing	System	1	2.2		
Total		46	100.0		

**E7**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Negatif	4	8.7	8.9	8.9
	Low	29	63.0	64.4	73.3
	High	12	26.1	26.7	100.0
	Total	45	97.8	100.0	
Missing	System	1	2.2		
Total		46	100.0		



### ANOVA

Age

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	2794.760	2	1397.380	9.803	.000
Within Groups	5987.151	42	142.551		
Total	8781.911	44			



# Post Hoc Tests

## Multiple Comparisons

Dependent Variable: Age

Bonferroni

(I) Diagnosis	(J) Diagnosis	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
LSIL	HSIL	1.64615	4.52426	1.000	-9.6358	12.9281
	SCC	17.08145*	4.39896	.001	6.1119	28.0510
HSIL	LSIL	-1.64615	4.52426	1.000	-12.9281	9.6358
	SCC	15.43529*	4.22951	.002	4.8883	25.9823
SCC	LSIL	-17.08145*	4.39896	.001	-28.0510	-6.1119
	HSIL	-15.43529*	4.22951	.002	-25.9823	-4.8883

\*. The mean difference is significant at the 0.05 level.

## E7 \* Diagnosis Crosstabulation

Count

		Diagnosis			Total
		LSIL	HSIL	SCC	
E7	Negatif	0	2	2	4
	Low	10	7	12	29
	High	3	6	3	12
Total		13	15	17	45

## Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	4.378 <sup>a</sup>	4	.357	.390		
Likelihood Ratio	5.471	4	.242	.346		
Fisher's Exact Test	4.234			.383		
Linear-by-Linear Association	.748 <sup>b</sup>	1	.387	.431	.242	.088

N of Valid Cases	45				
------------------	----	--	--	--	--

- a. 6 cells (66.7%) have expected count less than 5. The minimum expected count is 1.16.  
b. The standardized statistic is -.865.

### E7 \* PDL1 Crosstabulation

Count

		PDL1				Total
		Negatif	Low	Moderate	High	
E7	Negatif	3	1	0	0	4
	Low	5	20	3	1	29
	High	0	4	5	3	12
Total		8	25	8	4	45

### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	22.473 <sup>a</sup>	6	.001	.002		
Likelihood Ratio	20.876	6	.002	.002		
Fisher's Exact Test	17.152			.002		
Linear-by-Linear Association	15.616 <sup>b</sup>	1	.000	.000	.000	.000
N of Valid Cases	45					

- a. 8 cells (66.7%) have expected count less than 5. The minimum expected count is .36.  
b. The standardized statistic is 3.952.

**Crosstab**

Count

		Intensitas				Total
		Negatif	Low	High	3.00	
E7	Negatif	3	0	1	0	4
	Low	5	10	10	4	29
	High	1	2	2	7	12
Total		9	12	13	11	45

**Chi-Square Tests**

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	18.075 <sup>a</sup>	6	.006	.004		
Likelihood Ratio	16.606	6	.011	.017		
Fisher's Exact Test	13.312			.012		
Linear-by-Linear Association	9.071 <sup>b</sup>	1	.003	.002	.001	.001
N of Valid Cases	45					

a. 8 cells (66.7%) have expected count less than 5. The minimum expected count is .80.

b. The standardized statistic is 3.012.

**E7 \* Persentase**

**Crosstab**

Count

		Persentase				Total
		0	<10%	10-33%	>33%	
E7	Negatif	3	0	1	0	4
	Low	5	10	10	4	29
	High	1	2	1	8	12
Total		9	12	12	12	45

### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	21.408 <sup>a</sup>	6	.002	.001		
Likelihood Ratio	20.028	6	.003	.004		
Fisher's Exact Test	16.231			.002		
Linear-by-Linear Association	9.960 <sup>b</sup>	1	.002	.001	.001	.000
N of Valid Cases	45					

a. 8 cells (66.7%) have expected count less than 5. The minimum expected count is .80.

b. The standardized statistic is 3.156.

### PDL1 \* TILS\_Percentage Crosstabulation

Count

	TILS_Percentage			Total
	<5%	5-10%	>10%	
PDL1 Negatif	0	1	7	8
Low	3	10	12	25
Moderate	4	3	1	8
High	4	0	0	4
Total	11	14	20	45

### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	24.916 <sup>a</sup>	6	.000	.000		
Likelihood Ratio	25.843	6	.000	.000		
Fisher's Exact Test	19.741			.000		
Linear-by-Linear Association	18.931 <sup>b</sup>	1	.000	.000	.000	.000
N of Valid Cases	45					

a. 9 cells (75.0%) have expected count less than 5. The minimum expected count is .98.

b. The standardized statistic is -4.351.

### ANOVA

TILS\_Jumlah

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	29318.103	3	9772.701	7.705	.000
Within Groups	52004.875	41	1268.412		
Total	81322.978	44			

# Post Hoc Tests

## Multiple Comparisons

Dependent Variable: TILS\_Jumlah

Bonferroni

(I) PDL1	(J) PDL1	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
Negatif	Low	56.62500*	14.46679	.002	16.5180	96.7320
	Moderate	65.12500*	17.80738	.004	15.7566	114.4934
	High	90.12500*	21.80950	.001	29.6613	150.5887
Low	Negatif	-56.62500*	14.46679	.002	-96.7320	-16.5180
	Moderate	8.50000	14.46679	1.000	-31.6070	48.6070
	High	33.50000	19.17914	.529	-19.6714	86.6714
Moderate	Negatif	-65.12500*	17.80738	.004	-114.4934	-15.7566
	Low	-8.50000	14.46679	1.000	-48.6070	31.6070
	High	25.00000	21.80950	1.000	-35.4637	85.4637
High	Negatif	-90.12500*	21.80950	.001	-150.5887	-29.6613
	Low	-33.50000	19.17914	.529	-86.6714	19.6714
	Moderate	-25.00000	21.80950	1.000	-85.4637	35.4637

\*. The mean difference is significant at the 0.05 level.